Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,933,168
Introduction
U.S. Patent 4,933,168, granted on June 12, 1990, to Boehringer Mannheim GmbH (now part of Roche), represents a significant patent in the realm of biochemical diagnostic methods. The patent primarily covers immunoassay techniques for detecting specific analytes, notably employing monoclonal antibodies to improve assay specificity and sensitivity. Understanding the scope and claims of this patent provides valuable insights into its influence on subsequent diagnostic innovations and its relevance within the patent landscape.
Scope and Fundamental Claims of U.S. Patent 4,933,168
Core Technical Innovation
The patent's central innovation lies in the use of monoclonal antibodies for immunoassay detection of analytes. Unlike conventional polyclonal antibody methods, monoclonal antibodies offer enhanced specificity, reproducibility, and potential for automation—factors critical to commercial diagnostic assays.
Key Claims Overview
The patent encompasses multiple claims; notably, these include:
-
Claim 1: An immunoassay method for detecting a target analyte where a monoclonal antibody specific to the analyte is employed, and the antibody is labeled with a detectable marker. This claim emphasizes the fundamental assay architecture: monoclonal antibody binding combined with a detectable tag.
-
Claim 2: The method wherein the monoclonal antibody is immobilized on a solid support, facilitating separation of bound from free components—a core principle for sandwich immunoassays.
-
Claim 3: Specific labels, including enzymatic or radioactive markers, facilitating detection—broadening the scope of detectable signals.
-
Claims 4-10: Variations involving competitive binding formats, different immobilization strategies, and specific assay configurations, which serve to cover various embodiments of the assay.
Scope of Claims
The claims focus primarily on the use of monoclonal antibodies in immunoassays, whether in sandwich or competitive formats. They cover:
-
The utilization of monoclonal antibodies for analyte detection.
-
Labeled antibodies for detection purposes.
-
Immobilization of monoclonal antibodies on solid phases.
-
Specific detection methods compatible with the monoclonal antibody approach.
The scope is therefore centered on biochemical assay methods employing monoclonal antibodies, fundamentally foundational for subsequent immunodiagnostics.
Patent Landscape Analysis
Pre-Patent Context
Prior to 1990, immunoassays largely relied on polyclonal antibodies, which presented reproducibility challenges due to batch variability. The advent of monoclonal antibody technology (notably, Köhler and Milstein's 1975 patent [1]) revolutionized diagnostic assay development, providing opportunity for more standardized, high-specificity tests.
Post-Grant Development and Key Related Patents
-
Expansion of Monoclonal Antibody Immunoassays: Subsequent patents built on this invention to develop assays for specific analytes, including hormones (e.g., hCG, prolactin), tumor markers, and infectious disease agents.
-
European and Other Jurisdictions: Parallel patents were filed internationally, reflecting global interest in monoclonal antibody-based diagnostics, with many assuming similar claims or expanding on assay configurations.
-
Role in Commercial Diagnostics: Major diagnostic companies, such as Roche, Abbott, and Beckman Coulter, incorporated the teachings into commercial kits, generating robust patent thickets around immunoassay formats.
Recent Patent Trends
Over the last decade, the patent landscape shifted towards:
-
Enhanced formats: Incorporation of nanotechnology, novel labels, and multiplexing capabilities.
-
Method claims: Patent filings increasingly focus on automation, high-throughput screening, and point-of-care applications.
-
Legal Challenges: Some foundational patents, including those citing or building upon 4,933,168, have faced patent expirations, sparking liberalization of assay development.
Patent Citations and Influences
4,933,168 has been cited by numerous subsequent patents, affirming its foundational role in the field of monoclonal antibody immunoassays. These include diagnostic methods for detecting HIV, hepatitis viruses, and other pathogens, often involving modifications of the basic assay structure.
Implications for Strategic Patent Positioning
The patent's coverage, while broad at issuance, primarily protects fundamental assay methods employing monoclonal antibodies with labeled detection and immobilization features. In the current landscape, the patent’s expiration (most patents granted before 1995 have limited term remaining) opens the field for generic developments, but detailed claims surrounding specific analytes or formats continue to be heavily patented.
In practice, entities seeking to innovate in immunodiagnostics must navigate a landscape that includes:
-
Expiring foundational patents: Opportunities for open development.
-
Follow-on patents: Covering specific analyte applications, detection labels, or assay configurations.
-
Trade secret protections: For manufacturing processes or proprietary conjugates.
Conclusion
U.S. Patent 4,933,168 lays the groundwork for modern monoclonal antibody-based immunoassays. Its claims broadly encompass assay methods employing monoclonal antibodies labeled and immobilized for analyte detection, establishing a technological milestone. The patent landscape has evolved, with subsequent innovations building upon its foundational principles, and many claims now expired or nearing expiry, fostering an environment for innovation and generic production. Understanding this patent's scope is essential for industry players to identify freedom-to-operate opportunities and to design around or improve upon the original disclosure.
Key Takeaways
-
U.S. Patent 4,933,168 claims foundational immunoassay methods utilizing monoclonal antibodies, significantly advancing diagnostic assay specificity and reproducibility.
-
The patent’s scope covers antibody labeling, immobilization, and various assay formats, forming a basis for subsequent diagnostic innovations.
-
The patent landscape has evolved with new technologies, yet the core principles of monoclonal antibody immunoassays remain integral to modern diagnostics.
-
Many of the patent claims have expired, opening opportunities for development, though competitors must navigate remaining patent protections related to specific applications.
-
Strategic positioning requires analyzing both the expired foundational patents and current active patents protecting innovative assay formats or analyte-specific methods.
FAQs
1. When did U.S. Patent 4,933,168 expire, and what is its current status?
The patent was granted in 1990, and in the U.S., patent terms typically last 20 years from the filing date. Given standard patent term adjustments, it likely expired around the early 2010s, making its core claims generally in the public domain, though specific divisional or patent term adjustments may vary.
2. How does this patent influence current monoclonal antibody immunoassays?
It sets foundational principles for employing monoclonal antibodies with labels in immunoassays. Modern assays often build on or improve these concepts, adding multiplexing, automation, and novel labels, but the core patentings have influenced the entire field.
3. Are there any active patents directly citing U.S. Patent 4,933,168?
Yes. Many subsequent patents, especially those filed in the 1990s and 2000s, cite this patent, particularly for assay format improvements, labels, and specific analytes, indicating its ongoing influence.
4. What are the main competitive advantages of assays based on the principles of this patent?
High specificity, reproducibility, ease of automation, and suitability for high-throughput screening. These qualities have made monoclonal antibody-based immunoassays a mainstay in clinical diagnostics.
5. Can companies freely commercialize assays based on this patent today?
Generally yes, given the patent’s expiration. However, they must consider other active patents covering specific applications, detection labels, or assay formats that may still be in force.
References
[1] Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497.
